Novacyt Crecimiento futuro

Future controles de criterios 0/6

Actualmente no disponemos de suficiente cobertura de analistas para prever el crecimiento y los ingresos de Novacyt.

Información clave

n/a

Tasa de crecimiento de los beneficios

n/a

Tasa de crecimiento del BPA

Crecimiento de los beneficios de Biotechs	23.9%
Tasa de crecimiento de los ingresos	n/a
Rentabilidad financiera futura	n/a
Cobertura de analistas	None
Última actualización	n/a

Actualizaciones recientes sobre el crecimiento futuro

Recent updates

Little Excitement Around Novacyt S.A.'s (EPA:ALNOV) Earnings As Shares Take 25% Pounding

Sep 29

Novacyt's (EPA:ALNOV) Wonderful 999% Share Price Increase Shows How Capitalism Can Build Wealth

Mar 08

Is Novacyt S.A.'s(EPA:ALNOV) Recent Stock Performance Tethered To Its Strong Fundamentals?

Jan 22

Calculating The Intrinsic Value Of Novacyt S.A. (EPA:ALNOV)

Dec 15

We're Not Counting On Novacyt (EPA:ALNOV) To Sustain Its Statutory Profitability

Nov 19

En esta sección solemos presentar previsiones de crecimiento de ingresos y beneficios basadas en las estimaciones por consenso de analistas profesionales para ayudar a los inversores a comprender la capacidad de la empresa para generar beneficios. Pero como Novacyt no ha proporcionado suficientes datos anteriores y no dispone de previsiones de analistas, sus beneficios futuros no pueden calcularse de forma fiable extrapolando datos anteriores o utilizando las previsiones de los analistas.

Es una situación poco común, ya que el 97% de las empresas disponibles en SimplyWall St sí disponen de datos financieros anteriores.

Previsiones de crecimiento de beneficios e ingresos

ENXTPA:ALNOV - Estimaciones futuras de los analistas y datos financieros pasados (GBP Millions)
Fecha	Ingresos	Beneficios	Flujo de caja libre	Flujo de caja operativo	Núm. de analistas medio
6/30/2023	8	-25	-18	-18	N/A
3/31/2023	14	-24	-16	-16	N/A
12/31/2022	21	-22	-14	-14	N/A
9/30/2022	39	-11	5	6	N/A
6/30/2022	57	1	24	26	N/A
3/31/2022	75	-2	18	21	N/A
12/31/2021	93	-6	12	16	N/A
9/30/2021	179	40	39	42	N/A
6/30/2021	266	85	66	69	N/A
3/31/2021	272	109	84	86	N/A
12/31/2020	277	132	102	103	N/A
9/30/2020	173	83	61	62	N/A
6/30/2020	68	33	21	21	N/A
3/31/2020	40	15	10	10	N/A
12/31/2019	11	-3	-1	-1	N/A
9/30/2019	12	-3	-1	0	N/A
6/30/2019	13	-2	-1	0	N/A
3/31/2019	12	-2	-1	-1	N/A
12/31/2018	12	-2	-2	-1	N/A
6/30/2018	11	-3	-5	-4	N/A
3/31/2018	11	-3	-5	-4	N/A
12/31/2017	11	-3	-5	-4	N/A
9/30/2017	12	-4	-4	-3	N/A
6/30/2017	12	-3	-3	-3	N/A
3/31/2017	10	-4	N/A	-2	N/A
12/31/2016	9	-5	N/A	-2	N/A
9/30/2016	9	-9	N/A	-3	N/A
6/30/2016	8	-13	N/A	-3	N/A
3/31/2016	7	-12	N/A	-4	N/A
12/31/2015	7	-10	N/A	-4	N/A
9/30/2015	6	-7	N/A	-4	N/A
6/30/2015	6	-4	N/A	-4	N/A
3/31/2015	5	-3	N/A	-3	N/A
12/31/2014	4	-3	N/A	-2	N/A
9/30/2014	2	-2	N/A	0	N/A
6/30/2014	1	-1	N/A	0	N/A
3/31/2014	1	-1	N/A	0	N/A
12/31/2013	1	-1	N/A	-1	N/A
9/30/2013	1	-1	N/A	N/A	N/A
6/30/2013	1	-1	N/A	-1	N/A

Previsiones de crecimiento futuro de los analistas

Ingresos vs. Tasa de ahorro: Datos insuficientes para determinar si el crecimiento previsto de los beneficios de ALNOV es superior a la tasa de ahorro (1%).

Beneficios vs. Mercado: Datos insuficientes para determinar si se prevé que los beneficios de ALNOV crezcan más rápidamente que el mercado French

Beneficios de alto crecimiento: Datos insuficientes para determinar si se espera que los beneficios de ALNOV crezcan significativamente en los próximos 3 años.

Ingresos vs. Mercado: No hay datos suficientes para determinar si se prevé que los ingresos de ALNOV crezcan más rápidamente que el mercado de French.

Ingresos de alto crecimiento: No hay datos suficientes para determinar si se prevé que los ingresos de ALNOV crezcan a un ritmo superior a 20% al año.

Previsiones de crecimiento de los beneficios por acción

Rentabilidad financiera futura

ROE futura: Datos insuficientes para determinar si la rentabilidad financiera de ALNOV se prevé que sea elevada dentro de 3 años.

Novacyt Crecimiento futuro

Future controles de criterios 0/6

Información clave

Actualizaciones recientes sobre el crecimiento futuro

Novacyt S.A. Provides Group Revenue Guidance for the First Half Ended June 30, 2023

Novacyt S.A. Provides Group Financial Guidance for the Third Quarter and Year-To-Date Ended September 2022 and Fourth Quarter of 2022

Novacyt S.A. Reiterate Revenue Guidance for the Full Year

Novacyt S.A. Provides Sales Guidance for the Full Year 2021

Price target decreased to €4.90

Novacyt S.A. Provides Earnings Guidance for the Year 2021

Recent updates

Novacyt S.A. Notes DHSC Application for Summary Judgment Dismissed

New minor risk - Financial data availability

Novacyt S.A. Announces Changes to Its Board, Effective on May 1, 2024

New minor risk - Share price stability

Is Novacyt (EPA:ALNOV) In A Good Position To Deliver On Growth Plans?

First half 2023 earnings released: UK£0.12 loss per share (vs UK£0.071 loss in 1H 2022)

New major risk - Revenue and earnings growth

Novacyt S.A. to Report Q2, 2023 Results on Sep 28, 2023

Novacyt S.A. Provides Group Revenue Guidance for the First Half Ended June 30, 2023

We're Keeping An Eye On Novacyt's (EPA:ALNOV) Cash Burn Rate

Novacyt S.A., Annual General Meeting, Jun 15, 2023

Full year 2022 earnings released: UK£0.31 loss per share (vs UK£0.14 loss in FY 2021)

Now 23% undervalued after recent price drop

Novacyt S.A. to Report Fiscal Year 2022 Results on Apr 24, 2023

Estimating The Fair Value Of Novacyt S.A. (EPA:ALNOV)

Now 21% undervalued after recent price drop

Novacyt S.A. Announces Retirement of Non-Executive Director, Effective on 31 December 2022

Novacyt Announces Step Down of David Allmond as Member of the Board

Novacyt Announces Approval of genesig® SARS-CoV-2 Winterplex® 3 Gene Assay Panel in the UK Under CTDA Legislation

First half 2022 earnings released: UK£0.07 loss per share (vs UK£0.18 loss in 1H 2021)

Novacyt S.A. Provides Group Financial Guidance for the Third Quarter and Year-To-Date Ended September 2022 and Fourth Quarter of 2022

Novacyt S.A. to Report First Half, 2022 Results on Sep 29, 2022

Novacyt Announces the Launch of the First Fully Lyophilised (Freeze-Dried), Direct-To-PCR Assays

Novacyt S.A. Launches Research-Use-Only Adenovirus F41 Assay

Novacyt S.A. Announces Approval of exsig COVID-19 Direct test in the UK

Novacyt Announces the Launch of Its Research-Use-Only Polymerase Chain Reaction Monkeypox Assay in Response to the Recent Outbreak of the Virus in Non-Endemic Countries

Novacyt S.A., Annual General Meeting, Jun 21, 2022

Full year 2021 earnings released: UK£0.14 loss per share (vs UK£1.94 profit in FY 2020)

Novacyt S.A. Provides Update on DHSC Dispute

Novacyt Announces Approval of COVID-19 Test Under CTDA Legislation

CEO & Director recently bought €121k worth of stock

With EPS Growth And More, Novacyt (EPA:ALNOV) Is Interesting

Novacyt S.A. Announces Approval of the First Direct-To-PCR Covid-19 Test in the UK Under CTDA Legislation

Novacyt S.A. to Report Fiscal Year 2021 Results on Apr 25, 2022

Investor sentiment deteriorated over the past week

Investor sentiment improved over the past week

Investor sentiment deteriorated over the past week

With EPS Growth And More, Novacyt (EPA:ALNOV) Is Interesting

Investor sentiment improved over the past week

High number of new directors

Investor sentiment improved over the past week

Little Excitement Around Novacyt S.A.'s (EPA:ALNOV) Earnings As Shares Take 25% Pounding

Investor sentiment improved over the past week

Novacyt S.A. Reiterate Revenue Guidance for the Full Year

Full year 2020 earnings released: EPS UK£1.94 (vs UK£0.072 loss in FY 2019)

Novacyt S.A. Provides Sales Guidance for the Full Year 2021

Novacyt S.A. Announces the Launch of Two New Polymerase Chain Reaction Assays, Expanding its genesig® COVID-19 and SNPsig® SARS-CoV-2 Variant Detection Portfolios

Novacyt S.A. Announces Launch of VersaLab™ Portable

Investor sentiment deteriorated over the past week

Price target decreased to €4.90

Novacyt S.A. Announces Inclusion of SNPsig SARS-CoV-2 PCR Genotyping Portfolio in the NHS England Framework and Expansion of SNPsig Product Range

Investor sentiment improved over the past week

Novacyt S.A. Provides Earnings Guidance for the Year 2021

Investor sentiment deteriorated over the past week

Novacyt's (EPA:ALNOV) Wonderful 999% Share Price Increase Shows How Capitalism Can Build Wealth

New 90-day low: €7.93

Investor sentiment deteriorated over the past week

Novacyt S.A. Announces Launch of PCR Genotyping Assay Portfolio to Detect Covid-19 Variants

New 90-day high: €13.24

Is Novacyt S.A.'s(EPA:ALNOV) Recent Stock Performance Tethered To Its Strong Fundamentals?

Investor sentiment improved over the past week

Novacyt S.A. Announces Board Changes

Novacyt S.A. Appoints James McCarthy as Chief Financial Officer

Calculating The Intrinsic Value Of Novacyt S.A. (EPA:ALNOV)

Novacyt S.A. Announces the Development of Three Tests for New Strains of COVID-19 and Avian Influenza

Market bids up stock over the past week

We're Not Counting On Novacyt (EPA:ALNOV) To Sustain Its Statutory Profitability

CEO & Director recently bought €558k worth of stock

Market pulls back on stock over the past week